Q-omics provides the consensus-scored NFE2 profile across patient tissues and cancer cell-line models. NFE2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NFE2 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, NFE2 RNA expression shows 14,086 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, LUSC, and TGCT as cancer lineages where NFE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFE2 survival associations across molecular data types. NFE2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFE2 RNA expression–survival associations across cancer types. High NFE2 expression shows unfavorable associations in STAD, LGG, ACC and KIRP, but favorable associations in BRCA and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for NFE2 RNA expression.
This table summarizes NFE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NFE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFE2 shows lower tumor expression in LUSC and THCA and higher tumor expression in UCEC, HNSC, KIRP and COAD. The LUSC box plot shows higher NFE2 RNA expression in normal versus tumor tissue (log2 FC = −2.345, t-test p < 0.001).
This table shows molecular features associated with NFE2 in patient tissues and cancer cell lines. In patient samples, NFE2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NFE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
